Phathom Pharmaceuticals has been launched with $140m in debt and equity financing to commercialise a gastrointestinal disease drug licensed from Takeda.

Pharmaceutical firm Takeda and venture capital firm Frazier Healthcare Partners officially launched a US-based biopharmaceutical startup called Phathom Pharmaceuticals yesterday with $90m of crossover financing and $50m of debt financing. Frazier led the equity portion of the round, investing with Medicxi, RA Capital Management, Abingworth, Janus Henderson Investors, BVF Partners, Greenspring Associates, Richard King Mellon…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.